Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Mar 14;61(4):877–887. doi: 10.2337/db11-1391

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2012 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

PMC Copyright notice

FIG. 5. — Role of PPARs and CD36 in mitochondrial biogenesis. A: mRNA expression of PPAR isoforms determined by RT-qPCR using TaqMan probe in RC13 human rhabdomyosarcoma cell line (n = 4) and human skeletal muscle (n = 4). Data were normalized with 18S rRNA expression. B: RC13 cells were treated with CD36, PPAR-α, and PPAR-δ RNAi (50 nmol/L), maintained in 10% FBS RPMI for 48 h, fixed with 1% formaldehyde, stained with Mitotracker Green (which stain mitochondria specifically), and scanned with multifluorescence reader. The quantity of Mitotracker Green dye was divided by DAPI signal to normalize cell number. Results represent mean ± SEM. *P < 0.05, ***P < 0.0005 vs. nontargeting control. C: Mitochondrial protein expressions in L6 myotubes measured by Western blotting in control (nontargeting control 50 nmol/L; n = 6), LPL RNAi (LPL RNAi 25 nmol/L + nontargeting control 25 nmol/L; n = 6), CD36 RNAi (CD36 RNAi 25 nmol/L + nontargeting control 25 nmol/L; n = 3), combination of LPL and CD36 RNAi (LPL RNAi 25 nmol/L + CD36 RNAi 25 nmol/L; n = 3), PPAR-δ RNAi (PPAR-δ RNAi 25 nmol/L + nontargeting control 25 nmol/L; n = 3), and combination of LPL and PPAR-δ RNAi (PPAR-δ RNAi 25 nmol/L + nontargeting control 25 nmol/L; n = 3). Cyt-c, cytochrome c. D: mRNA expression of MTCOI determined by RT-qPCR in L6 myotubes after RNAi treatment against control (nontargeting control 50 nmol/L; n = 3), LPL RNAi (LPL RNAi 25 nmol/L + nontargeting control 25 nmol/L; n = 3), and CD36 RNAi (CD36 RNAi 25 nmol/L + nontargeting control 25 nmol/L; n = 3). E: mRNA expression of MTCOI determined by RT-qPCR in L6 myotubes after RNAi treatment against control (nontargeting control 50 nmol/L; n = 3), LPL RNAi (LPL RNAi 25 nmol/L + nontargeting control 25 nmol/L; n = 3), PPAR-δ RNAi (PPAR-δ RNAi 25 nmol/L + nontargeting control 25 nmol/L; n = 3), and combination of LPL and PPAR-δ RNAi (PPAR-δ RNAi 25 nmol/L + nontargeting control 25 nmol/L; n = 3). Results represent mean ± SEM. *P < 0.05, **P < 0.005, ***P < 0.0005.